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Amikacin (AK) and enrofloxacin (EF) concentrations consistent with intraarticular and regional limb perfusion were evaluated for their effects on equine
chondrocytes. We evaluated the production of prostaglandin E2 (PGE2) by equine
chondrocytes in response to AK and EF administration, and if the combination of
avocado soybean unsaponifiables (ASU), glucosamine (GLU), and chondroitin sulfate
(CS) could reduce the production of PGE2. Monolayer cell cultures of equine
chondrocytes were treated with clinically relevant concentrations of AK and EF plus
combinations of ASU, GLU, and CS. AK and EF generated a dose dependent
cytotoxicity. The induction of PGE2 following EF administration was significantly
greater than PGE2 levels induced by positive controls. Induction of PGE2 by EF was
significantly reduced in chondrocytes pretreated with ASU, GLU, and CS. We have
demonstrated for the first time that EF can induce production of PGE2 in equine
chondrocytes and that this effect can be attenuated with the combination of ASU, GLU,
and CS.
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CHAPTER I
INTRODUCTION
Degenerative joint disease is a common cause of lameness and joint pain in the
horse. Destruction of the articular cartilage and disruption of the subchondral bone is the
result of inflammation within the synovial structure. This destruction originates from
multiple different modalities. Most commonly, osteoarthritis in the horse is the result of
chronic inflammation from repetitive use or traumatic injury. However, on more rare
occasions, osteoarthritis can develop from non-traumatic, septic origins. Ultimately the
goals of managing degenerative changes within the joint are to modulate the destructive
inflammatory response.
Septic arthritis is a debilitating orthopedic condition. In adult horses, septic
arthritis most often results from synovial bacterial contamination via wounds, or
iatrogenic induction following arthroscopy or intra-articular injections.1-4 Septic arthritis
is a common consequence of bacteremia and septicemia in foals.1, 2, 5 In one study, septic
arthritis was identified as the cause of death in 12.5% of foals aged 8 to 31 days.5 Septic
arthritis is bacterial in origin. Streptococcus species and Staphylococcus aureus are the
most common isolates in adult horses.1, 2 The most frequent bacterial isolates cultured in
foals are Actinobacillus, E.coli, Klebsiella, Pseudomonas, and Salmonella.5
Septic arthritis causes such profound inflammation within the joint that articular
cartilage and subchondral bone are destroyed, often resulting in persistent lameness and
loss of athletic potential. The management goals for septic arthritis are immediate
1

identification and elimination of the infection as well as prompt reduction in
inflammation.1-3 Treatment includes joint lavage with a balanced electrolyte solution,
intra-articular antibiotics and systemic antimicrobials.1-3 Outcome of treatments are
variable with 25% to 55% returning to athletic soundness in one report.4 The goals of
treatment are to improve performance outcomes through aggressive antimicrobial therapy
delivered systemically, intra-articularly, or via regional limb perfusion. Although the
hallmark of managing septic arthritis is intra-articular antimicrobial drugs, minimal
information is available about the effects of these drugs on equine chondrocytes.
This project was undertaken to identify the potential harmful effects of two intraarticular anti-microbial drugs and determine if these negative effects could be attenuated
by the use of nutraceuticals as discussed in Chapter 3. Traditionally the harmful effects
of intra-articular antimicrobial drug have been evaluated with the observation of
lameness following administration, as well as macroscopic changes on post mortem
examination. The goal of our study is to evaluate the potential harmful effects on a more
sensitive scale by measuring the production of PGE 2, an inflammatory mediator and the
cytotoxic effects of these antibiotics on equine chondrocytes.
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CHAPTER II
ANTIMICROBIAL MANAGEMENT IN SEPTIC ARTHRITIS
Septic arthritis is a very debilitating and overwhelming disease. Intra-articular
antibiotics are utilized not only to treat septic arthritis, but in some cases to prevent the
development of a septic joint following arthroscopy or intra-articular medications. Only
a few antibiotics have been evaluated for their bioavailability, pharmacokinetics, and
effects on the equine joint. To date, information about the use of antibiotics in equine
joints has been published in regard to the following medications: gentamicin1-7,
amikacin8-10, ampicillin11, enrofloxacin12-15, ceftiofur16, trimethoprim sulfadiazine17 and
cefotaxime18.
The most commonly evaluated antibiotics in equine literature are the
aminoglycosides amikacin and gentamicin. These antibiotics are the most popular for
their apparent systemic tolerance, gram-negative spectrum of activity, and effective
concentration against most equine pathogens. Both amikacin and gentamicin irreversibly
bind to the 30S ribosomal unit of bacteria preventing protein synthesis.19 They are water
soluble and have a high volume of distribution into the extracellular fluid. This is a
favorable trait for drugs used within synovial fluid. Aminoglycosides are minimally
protein bound, which decreases the likelihood that they would be inhibited by plasma
proteins. The bactericidal effects of aminoglycosides are concentration dependent.19 In
the treatment of septic arthritis multiple days of systemic dosing to maintain
concentrations of aminoglycosides great enough to be effective can have undesirable
4

systemic effects. The most clinically significant toxicity is renal tubular necrosis from
repetitive elimination through the kidney.19 In attempts to maintain higher local
concentrations without systemic accumulation, these drugs are administered intraarticularly. Administration of gentamicin within the joint has been associated with mild
transient synovitis. Twenty-four hours following administration, significant increases in
synovial white blood cells and a remarkable drop in synovial fluid pH have been
documented.1, 2 Gentamicin has been evaluated for its effects on equine joints following
five days of continuous intra-articular administration. At the end of this period, the
articular cartilage and synovial membranes were (tested or examined) for loss of
glycosaminoglycan content and synovial membrane inflammation.4 There was no
difference between the gentamicin treated animals and the control animals. Therefore,
gentamicin is perceived to be minimally inflammatory. Most pharmacokinetic studies of
gentamicin indicated that not only synovial fluid concentrations remain around the
minimal inhibitory concentration (MIC), but that the subchondral bone concentrations do
as well.3-7 These concentrations are difficult to achieve with systemic administration of
gentamicin.
Amikacin is the most commonly administered intra-articular aminoglycoside in
equine practice due to the perceived tolerance as well as its convenient packaging -in a
2ml sterile vial and relatively low cost. These traits make it the initial antibiotic of choice
in prevention and treatment of septic arthritis. Amikacin has been evaluated in several
studies for its pharmacokinetics and effects in the equine joint.8-10 The therapeutic
concentrations are targeted at the MIC of the selected bacteria. The MIC is the
concentration of drug required to inhibit growth of a specific bacteria. Most equine
publications critically evaluating the effectiveness of an antibiotic evaluate the MIC of
5

Pseudomonas species.20 This is because of Pseudomonas’s fairly resistant nature to many
antibiotics and its likelihood of creating persistent infections. Amikacin has been shown
to maintain levels above the MIC for Pseudomonas sp. of 4 µg/ml for 24 hours following
a single intra-articular injection.8, 9 Administration of 500mg of amikacin into a normal
joint has been demonstrated to maintained concentrations greater then 4 ug/ml for up to
72 hours with no indications of inflammation, such as elevation in synovial fluid cell
counts or protein or onset of lameness.9 Although amikacin appears to be noninflammatory to the equine joint, all of these studies have evaluated only gross
pathological changes and overt lameness. One significant limitation to amikacin is its
gram negative spectrum, preventing successful treatment of the gram positive species of
organisms like Streptococcal and Staphylococcal species that commonly plague the
equine joint.20
Another antibiotic that would be favorable for orthopedic infections due to its
antimicrobial spectrum and large volume of distribution is enrofloxacin. Enrofloxacin is a
fluoroquinolone that inhibits DNA-gyrase.21 It prevents super-coiling of the DNA
molecules to prevent replication of bacteria.21 Enrofloxacin is highly lipid soluble which
allows for a large volume of distribution and bone penetration. This makes it a favorable
drug for orthopedic infection. The pharmacokinetics of enrofloxacin after oral and
intravenous administration has been reported to achieve concentrations of 1-5ug/ml in
peripheral tissues.13, 14, 22 The use of enrofloxacin for regional limb perfusions has been
investigated in which the greatest synovial fluid concentrations were detected
immediately after administration: values ranged from 7- 216 ug/ml.22 Concentrations
within the synovial fluid exceeded MIC for approximately 24 hours.22
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Enrofloxacin appears to be a favorable candidate for use in the treatment of septic
arthritis; however, it’s effect on chondrocytes after intra-articular administration is
unknown. Fluoroquinolones have demonstrated that at various concentrations they may
cause inflammation, cell death, and proteoglycan loss in chondrocytes and synovial
structures.14,15 These adverse effects have been observed on articular cartilage in rats,
dogs and foals.12-15, 21, 22 Beluche demonstrated that concentrations of enrofloxacin
consistent with systemic (intravenous) doses did not suppress chondrocyte growth, but
higher concentrations were toxic to chondrocytes.14 Concentrations of enrofloxacin
greater than 1000ug/ml eliminated proteoglycan synthesis regardless of animal age.
Additionally, these elevated concentrations (1000ug/ml) resulted in a significant number
of pyknotic nuclei within the chondrocytes, indicating cell death.14
High concentrations of antibiotics in joints have been associated with the
development of lameness and elevated synovial fluid cell counts.1-3, 12 In vitro studies
have indicated that antibiotics can induce proteoglycan loss and cytotoxicity in
chondrocytes.14, 15 Proteoglycan loss, which is indicative of extracellular matrix (ECM)
breakdown, has been attributed to production of pro-inflammatory mediators capable of
inducing degradative enzymes. Chondrocytes, the only cell constituent of cartilage,
synthesize pro-inflammatory mediators such as prostaglandin E2 (PGE2) and other ECM
degradative enzymes. Excessive production of these mediators and enzymes lead to
articular cartilage breakdown.
Evaluation of the ability of antibiotics to induce inflammatory mediators would
allow for the development of strategies to minimize antibiotics potential adverse effects
on equine joints. Therefore, the objective of this study is to clarify the role of amikacin
and enrofloxacin in inducing inflammation. Amikacin and enrofloxacin concentrations
7

consistent with intravenous, intra-articular and regional limb perfusions were evaluated
for their effect on equine chondrocytes. We tested the hypothesis that chondrocytes
treated with these particular concentrations of amikacin and enrofloxacin would produce
PGE2, a pro-inflammatory marker, in response to the antibiotic.
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CHAPTER III
NUTRICEUTICAL AND THE CONTROL OF OSTEOARTHRITIS
We have demonstrated that osteoarthritis is an important cause of lameness in
horses. Although a number of factors can initiate the disease process, the hallmark of the
disease is the degeneration of the articular cartilage and its matrix. This degeneration is
attributed to the excess production of proinflammatory cytokines like PGE2 and
interleukin-1β (IL-1β). Over production of these cytokines stimulates cartilage matrix
degradation by inhibiting the production of proteoglycan and type II collagen while up
regulating aggrecanase, which perpetuates matrix destruction.1 Because cartilage
degeneration is directly linked to levels of inflammatory mediators, evaluating
compounds that alter these proinflammatory mediators is a promising treatment strategy
in managing the progression of osteoarthritis (OA). PGE2is an important mediator in the
pathologic process of arthritis and cultured chondrocytes respond to interleukin-1 (IL-1)
with enhanced expression and activity of cyclooxygenase-2.2 Palliative relief in affected
horses is attributable in part to the reduction of PGE2 synthesis.2
Oral administration of nutraceuticals containing glucosamine and chondroitin
sulfate has received considerable attention as a palliative treatment of humans with OA.
Ongoing research in oral administration of neutraceuticlas indicates that both
glucosamine and chondroitin sulfate have chondroprotective and articular sparing
properties. Glucosamine acts as a substrate for the production of proteoglycans and
glygcosaminoglycans. It has been demonstrated that synovial concentrations achieved
14

via oral administration of glucosamine significantly reduced the production of the
inflammatory mediators IL-1β and aggrecanse-1 in equine chondrocytes.3 Although
chondroitin sulfate has a less explicit mode of action it has been associated with
glucosamine in its ability to minimize matrix degradation. This combined ability to alter
the catabolism of the ECM had been demonstrated in several studies by reducing
inflammatory mediators.2-4 Chan demonstrated that glucosamine and chondroitin sulfate
altered the production ofPGE2 , COX-2, and aggrecanase in long term bovine
chondrocyte explant cultures.4 Furthermore glucosamine and chondroitin sulfate have
also been observed to down regulate the expression of recombinant equine IL-1β in
monolayer chondrocyte cultures.3
Within the last twenty years another oral nutraceutical, avocado soybean
unsaponifiables(ASU) has been evaluated for its potential role in the prevention and
management of OA. Although currently the mechanism of action is not thoroughly
understood, the avocado soybean unsaponifiables were initially evaluated as a potential
chondroprotective agent. These chondroprotective effects were demonstrated in a human
study where ASU preserved the glygcosaminoglycan and hydroxyproline content of
theECM.5 Several human dietary trials began utilizing ASU as a chondroprotective and
preventative to OA.
In 1997 Blotman performed a double blind placebo controlled study evaluating
the effects of ASU on humans with osteoarthritis of the knee.6 The initial hypothesis of
this study was that the ASU would promote repair of the cartilage ECM. However, the
key finding in Blotman’s study was that all patients on the ASU had a significant
reduction in the daily use of non-steroidal anti-inflammatories. This finding seemed to
demonstrate that ASU may not only have chondroprotective effects but also appeared to
15

have significant anti-inflammatory effects.6 Later ASU began to be evaluated directly for
its role in modulating inflammation. Nutramax Laboratories demonstrated the ability of
ASU to alter PGE2 productions by 40% in chondrocyte monolayer cell cultures as well as
suppressing TNF-α, IL1-β, and COX-2. The same study showed a reduction in COX-2
expression by 50%.7 ASU has exhibited a remarkable ability to reduce several markers of
inflammation and key components of OA. The combined anti-inflammatory effects of
ASU with the chondroprotective characteristics of glucosamine and chondroitin sulfate
are the basis for the modulation of inflammation in our study. Our hypothesis is that the
addition of ASU and glucosamine and chondroitin sulfate to equine chondrocyte cultures
will minimize the inflammation induced by the antibiotics.
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CHAPTER IV
METHODOLOGY
The use of antibiotics within synovial structures is paramount for the treatment
and prevention of septic arthritis. As discussed in previous chapters, minimal
information is available about the potential deleterious effects of antibiotics on equine
chondrocytes. Our first goal in this study is to evaluate the effects of amikacin and
enrofloxacin at concentrations consistent with intra-articular and regional limb perfusion
on equine chondrocytes. We will determine if there are concentrations of these drugs that
are cytotoxic to chondrocytes. Our second goal is to assess the role of gentamicin and
enrofloxacin in inflammation by measuring the production of PGE2 by equine
chondrocytes treated with these antibiotics and determine if the production of PGE2 could
be reduced by the combination of avocado soybean unsaponifiables (ASU), glucosamine
(GLU), and chondroitin sulfate (CS).
Materials and Methods
Cell Culture
Equine cartilage was aseptically diced into <5 mm pieces and digested in type II
collagenase (110 U/ml) for 12-18 hours at 37°C, 5% CO2. Chondrocytes were filtered
through a wire mesh screen to remove debris and rinsed four times with Hank’s Balanced
Salt Solution (HBSS) (ATCC; Manassas, VA, USA). Cells were counted and assessed
for viability using the Trypan-blue exclusion method. Chondrocytes were propagated in
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monolayer culture until confluency in media composed of Dulbeccos’ Modified Eagle’s
basal medium (Sigma; St. Louis, MO, USA) supplemented with 10% fetal bovine
serum(Gemini Bio-Products; Woodland, CA, USA), 300 μg/ml L-glutamine(Sigma), and
3.7 g/L sodium bicarbonate (Sigma). When confluent, chondrocytes were propagated in
monolayer culture until ready for use.
Phenotype Analysis by Immunohistochemistry and Western Blot Analysis
Chondrocytes were plated on microscope slides and fixed with 10%
paraformaldehdye. Slides were then incubated with goat anti-type I collagen, anti-type II
collagen, or anti-aggrecan antibodies (Southern Biotechnology Associates; Birmingham,
AL, USA). The slides were next washed in buffer three times and incubated with FITC
labeled anti-goat antibodies. Immunostaining was visualized using a Nikon Eclipse
epifluorescent microscope TE200. To identify secreted collagen and aggrecan, spent
culture media were electrophoresed on 4-15% sodium dodecyl sulfate-polyacrylamide
gels. Following electrophoresis, the gels were electrophoretically transferred to
PolyVinylidine DiFluoride (PVDF) membranes (Bio-Rad Laboratories, Hercules, CA,
USA) in Tris-glycine buffer, pH 8.5, containing 20% methanol. Blotted PVDF
membranes were washed twice with deionized water and stained using a chromogenic
Western blot immunodetection kit (Gibco Invitrogen, Carlsbad, CA, USA). To block
non-specific staining, membranes were treated with a blocking solution provided with the
immunodetection kit following the instructions of the manufacturer. PVDF membranes
were then processed for immunostaining using goat anti-collagen type II, type I
antibodies, or anti-aggrecan (Southern Biotechnology Associates) in combination with an
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alkaline phosphatase labeled rabbit anti-goat antibody with 5-bromo-4-chloro-3indolylphosphate-nitroblue tetrazolium (BCIP/NTB) (Gibco Invitrogen) as the substrate.
Experimental Design
ASU (ASU-NMX® 1000; Nutramax Laboratories, Inc., Edgewood, MD, USA)
was dissolved in 100% ethanol (Sigma) and diluted with HBSS (GIBCO) to achieve the
required final concentration. The concentration used in this study was previously shown
to exert significant anti-inflammatory effect (Au et al, 2007).1 Glucosamine (FCHG49®,
Nutramax Laboratories Inc.) and chondroitin sulfate (TRH122®, Nutramax Laboratories
Inc.) were dissolved in HBSS (GIBCO) to achieve the working concentrations.
Chondrocytes harvested from monolayer cultures were first seeded into 6 well (5
x 105) and 24 well (1x105) plates for 24 hours. The monolayer cultures were next
incubated with: control media alone or ASU (8.3 μg/ml), Glu (11 μg/ml), and CS (20
μg/ml) for another 24hrs. Following pretreatment, lipopolysaccharide (LPS, 20ng/ml;
Sigma-Aldrich) or IL-1β (10ng/ml) and TNFα (1ng/ml) was added as a positive control.
Enrofloxacin (0.1mg/ml-10mg/ml) (Sigma) or amikacin (0.25mg/ml-25mg/ml) (Sigma)
was added with or without the combination of ASU, Glu, and CS for another 24 hrs to
measure secreted PGE2 levels by immunoassay or determine cytotoxicity through MTT
cell proliferation assay. 10% EtOH was added in triplicates to the 24 well plates as a
positive control of cell death.
MTT Cell Proliferation
To determine whether or not enrofloxacin or amikacin caused cell death, a MTT
cell proliferation assay kit (Cayman Chemical) was used to measure cytotoxicity. The
cellular supernatant was aspirated off from the 24 well plates. 1ml of sterile HBSS and
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100μl of reconstituted MTT were then added to each well. Plates were incubated at
37°C, 5% CO2 for 3hrs. After 3hrs 1ml of MTT solubilization solution was added and
thoroughly mixed. Plates were allowed to sit in room temperature for at least 15 minutes
to allow crystal dissolution. The contents of the well were again mixed thoroughly and
200μl aliquots were plated in triplicates into a 96 well plate. Absorbance was measured
using a Spectramax Plus (Molecular Devices, Sunnyvale, CA, USA) at a double
wavelength of 570nm and 690nm.
PGE2 High Sensitivity Immunoassay
A commercial PGE2 immunoassay (R&D Systems, Minneapolis, MN USA) was
used to quantify secreted PGE2 levels in the cellular supernatant, according to the
manufacturer’s instructions. A PGE2 standard was run in parallel to the supernatant
samples. Briefly, 100 μl of each supernatant sample was assayed in triplicates on a 96well microplate coated with a goat anti-mouse polyclonal antibody. 50 μl of PGE2 HS
conjugate was added to each sample well. Next, 50 μl of PGE2 antibody solution was
added to each sample well. The microplate was incubated for 18-24 hrs at 2-8°C. After
the incubation period, the microplate wells were aspirated and washed with PGE2 wash
buffer for a total of three washes. After the last wash, 200 μl of pNPP ubstrate was added
to the microplate wells. After incubation for 20min at room temperature, 50 μl of Stop
Solution was added to the sample wells. Optical density was measured immediately using
the SpectraMAX 340 microplate reader (Molecular Devices, Sunnyvale, CA, USA) at
405 nm with wavelength correction set between 570 nm and 590 nm.
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Statistical Analysis
Data is presented as the mean ± 1 SD. Pair-wise multiple comparisons were
carried out using Student-Neuman-Keuls one-way ANOVA and Tukey post-hoc using
SigmaStat statistical software (Windows Version 3.11) where p<0.05 was considered
statistically significant.
Results
Phenotype Characterization of Chondrocyte Monolayer Culture
Equine chondrocytes proliferated with ease in monolayer culture with 100%
viability. The doubling time for monolayer cultures was three to five days. Chondrocytes
propagated on monolayer cultures at passage 3 showed elongated, spindle-shaped
morphology (Figure 4.1). Immunohistochemical analysis confirmed that chondrocyte
cultures continued to produce the ECM components aggrecan and type II collagen
(Figure 4.2 and 4.3, respectively). Production of type II collagen was further verified by
Western blot. Chondrocyte cultures showed negligible production of type I collagen. The
high molecular weight aggrecan protein did not enter the gel and could not be visualized
on Western blot.
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Figure 4.1

Phase-contrast photomicrograph of equine chondrocyte culture
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Figure 4.2

Immunostaining for type II collagen

Figure 4.3

Immunostaining for aggrecan
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The Cytotoxic Effect of Amikacin and Enrofloxacin on Equine Chondrocytes
Amikacin and enrofloxacin both have dose dependent cytotoxic effects on equine
chondrocytes. Optical density measurements for amikacin demonstrated no difference
from the control non-activated cells at the concentration of 0.25 mg/ml. Chondrocytes
treated with 2.5mg/ml concentrations of amikacin demonstrated an increase in cell death
by approximately 40%. Cells treated with 25 mg/ml concentrations of amikacin
demonstrated profound cytotoxicity, with 99% cell death (Figure 4.4). Low dose
concentrations of enrofloxacin (0.1mg/ml) demonstrated an increase in cell death by
40%. Concentrations of enrofloxacin at (1.0mg/ml) increased cytotoxicity by 82% and
concentrations of enrofloxacin at 10 mg/ml were severely cytotoxic with 99% cell death.
(Figure 4.5).

Figure 4.4

Effect of Amikacin (0.25, 2.5 and 25 mg/ml) on chondrocyte cytotoxicity
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Figure 4.5

Effect of Enrofloxacin (0.1, 1.0 and 10 mg/ml) on chondrocyte cytotoxicity

The Effect of Amikacin and Enrofloxacin on PGE2 Production by Equine Chondrocytes
Chondrocytes treated with various concentrations of amikacin (0.25, 2.5 and
25mg/ml) did not induce significant production in PGE2 when compared to the control
non-treated chondrocytes during the 24 hours of incubation. In contrast, enrofloxacin
dramatically induced PGE2 production in a dose dependent fashion. Chondrocytes
responded to enrofloxacin at concentrations of 0.1, 1.0 and 10 mg/ml with a significant
increase in PGE2 production (p<0.001, Figure 4.6). The synthesis of PGE2 following
exposure of chondrocytes to enrofloxacin was significantly greater than PGE2 levels
induced by LPS (< 20 fold) or cytokines IL-1β and TNF-α (<5 fold). Treatment of
chondrocytes with 0.1mg/ml of EF resulted in the production of PGE2 at 28,000 pg/ml.
Concentrations of 1.0mg/ml resulted in the production of 48,000 pg/ml PGE2. Most
significant production of PGE2 was at 160,000 pg/ml from the 10 mg/ml concentration of
enrofloxacin.
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Figure 4.6

PGE2 production in response to enrofloxacin at concentrations of 0.1, 1.0
and 10 mg/ml with a significant increase in (p<0.001)

Induction of PGE2 synthesis by enrofloxacin was significantly (p<0.05) downregulated when chondrocytes were pre-treated with the combination of ASU, GLU, and
CS. Pre-treatment with ASU (8.3 µg/ml) and glucosamine and chondroitin sulfate at
concentrations ranging from 4 to 400 ng/ml significantly decreased PGE2 production at
0.1 mg/ml and 1.0 mg/ml concentrations of enrofloxacin (p>0.05, Figure). The
combination of ASU at 8.3µg/ml with EGCG at concentrations 4 to 400 ng/ml
significantly reduced PGE2 production relative to the activated control IL-1β and TNF-α
(p< 0.05, Figure 4). The combination of ASU at 4 µg/ml and EGCG at 40 ng/ml to the
10 mg/ml concentrations of enrofloxacin did not reduce PGE2 production.
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CHAPTER V
CONCLUSIONS
Our study demonstrated a significant increase in PGE2 following administration
of all concentrations of enrofloxacin. The expectation had been that the elevated levels
of enrofloxacin would induce an inflammatory response. Enrofloxacin was chosen as
one of the antimicrobials to be utilized in this study due to the spectrum of activity, the
volume of distribution, and the previous association with harmful effects on
chondrocytes. Bertone, et al. (2000) studied the effects of long term administration of
systemic enrofloxacin on lameness and the response of articular cartilage in the horse.
Within her study, mild swelling was observed in 1 or more joints in 9 horses after
administration of enrofloxacin, and lameness developed in 3 treated animals and then
resolved before the treatment period ended.1 Arthroscopic evaluation of affected joints
was normal on gross examination.1 However, the evidence of mild joint swelling within
the study population suggested that even though there were no macroscopic changes,
mild inflammation had occurred. The goal of our study was to demonstrate evidence of
antibiotic-induced inflammation through more sensitive measures.
The manufacturer’s recommended dosage of enrofloxacin is 5.0mg/kg
administered intravenously which generates a concentration of 2 to 10 ug/ml within the
peripheral tissues.2,3 The same dosing regime was observed to generated peak serum
concentration of 4-7 ug/ml and peak synovial concentrations of 1-4ug/ml 8 to 24 hours
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post administration.2 Synovial fluid concentrations of enrofloxacin achievable by
regional limb perfusions range from 7- 216 ug/ml.4
One study demonstrated that concentrations of enrofloxacin greater than 10 ug/ml
decreased chondrocytes’ ability to adhere to culture dishes.5 Chondrocyte cell size was
reduced and the actin cytoskeleton decreased with increasing concentrations of
enrofloxacin, as well as a reduction in type-2 collagen.5 These repeatable negative
effects of enrofloxacin demonstrate that synovial concentrations consistent with parental
administration of enrofloxacin elicit inflammatory and cytotoxic responses in
chondrocytes. Based on these previous clinical findings and the findings of our study,
enrofloxacin does induce inflammation that is harmful to chondrocytes. We were
successful at stimulating the production of PGE2 at all of our treatment concentrations of
enrofloxacin. Additionally at concentrations greater than 0.1mg/ml, cytotoxicity was also
observed.
Once inflammation was successfully induced the next objective of our study was
to modify these inflammatory responses. Several modulators of inflammation have been
identified in osteoarthritis. Avocado-soybean unsaponifiables, glucosamine, and
chondroitin sulfate are just a few currently available. Previous evaluation of avocadosoybean unsaponifiables at concentrations of 8.3 µg/ml added to bovine monolayer cell
cultures reduced TNFα, IL-1β, COX-2 and iNOS expression in LPS-activated
chondrocytes to levels similar to non-activated control levels. The suppression of COX-2
and iNOS expression was paralleled by a significant reduction in PGE2.6
Glucosamine, at concentrations of 10 ug/ml, significantly reduces expression of
MMP13 , aggrecanase-1, and cytokine-induced expression of nitric oxide and
cyclooxygenase-2.7 In our study we treated cells with glucosamine and chondroitin
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sulfate at concentrations ranging from 4 to 400 ng/ml. Synovial fluid concentrations of
glucosamine at 10 ug/ml are obtainable through oral administration.6 Others have
demonstrated that cartilaginous disks treated with glucosamine and chondroitin sulfate
decrease nitric oxide release and reduce nitric oxide synthase, cyclooxygenase-2, and
PGE synthase production.8 This down regulation of inflammatory mediators driven by
glucosamine and chondroitin sulfate are helpful in the management of synovial
inflammation.
Our study demonstrated a significant reduction of chondrocyte PGE2 expression
in the presence of enrofloxacin concentrations equal to and less than 1.0mg/ml following
the addition of ASU, GLU, and CS to cell cultures. PGE2concentrations were reduced to
baseline levels of less than 10,000pg/ml. Only at 10 mg/ml concentrations of
enrofloxacin were we unable to attenuate the deleterious effects. The potential benefits
of reducing PGE2 production at concentrations of enrofloxacin less than 1.0mg/ml with
the additions of ASU, GLU, and CS are the reduction in inflammation and the availability
of these products. Furthermore, they may be added to concurrent septic arthritis
treatment plans regardless of the antimicrobial used.
One potential downfall of this study is the treatment time period of the
chondrocyte cell cultures. All cultures were treated for 24 hours. Most literature of
regional limb perfusions indicated that peak synovial concentrations are obtained
approximately 60 minutes post administration and then begin to taper dramatically in the
next 24 hours. Our cells were exposed to enrofloxacin for a longer duration than regional
limb perfusions. This may account for the profound induction of PGE2. However, if this
is the case, then regardless of the exposure period still successfully reduced the
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expression of PGE2 in the face of significant inflammation with the additions ofASU,
GLU, and CS.
Amikacin was the next drug of choice due to its success in treating orthopedic
infections. A study of bacterial species isolated from septic arthritis, tenosynovitis and
osteomyelities in 233 horses yielded Enterbacteriaciae, beta-haemolytic streptococci and
coagulase-negative staphylococci as the predominant species isolated.9 Within this study
amikacin was the most effective antibiotic against the wide range of bacteria isolated.9
Amikacin was highly effective against coagulase-positive staphylococci,
Enterobacteriaceae and Psuedomonas. Gentamicin was not highly effective against any
bacterial group.9 Isolated limb retrograde venous injection yielded synovial
concentrations of amikacin ten times the minimum inhibitory concentration for 90% of
isolates (80 ug/ml) and ten times the MIC breakpoint (160 ug/ml) of amikacin-susceptible
bacteria reported to cause septic arthritis in horses.10 This technique achieved synovial
fluid concentrations of amikacin consistent with concentration dependent killing of
bacteria commonly encountered in horses with septic arthritis.10
Our study demonstrated that amikacin did not induce the production of PGE2
levels/concentrations that were greater than the levels/concentrations of the control nontreated cells at any of the study concentrations. Additionally cytotoxicity was only
observed at the greater concentrations of amikacin. These findings indicates that the use
of amikacin for regional limb perfusion and intra-articular injections is relatively safe and
unlikely to induce inflammation.11 Solidifying amikacin as the gold standard of
antimicrobials for the treatment of septic arthritis.
Treatment of septic arthritis in horses can be a difficult and expensive
undertaking. Unresolved infection and inflammation leading to joint damage can end a
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horses’ athletic career or even its life. Successful treatment depends on many factors
including the efficacy of the chosen antimicrobial and tissue concentrations of the
antimicrobial administration. Resolution of infections requires delivery of an
antimicrobial to the target tissues in concentrations greater than the MIC for the bacteria4.
In equine practice, local delivery of antimicrobials for the treatment of septic arthritis is
used to supplement or replace systemic administration. Local delivery techniques are
favored because they are capable of achieving high tissue concentrations of
antimicrobials at the site of infections while reducing undesirable systemic effects. The
ability to deliver high tissue concentrations of drug for an appropriate time interval
results in maximum bacterial killing and reduced bacterial resistance.10
In the present study, we have shown for the first time that enrofloxacin can induce
production of PGE2 in equine chondrocytes. This induction of PGE2 synthesis can be
attenuated with the combination of ASU, GLU, and CS. Our observation that the
combination of ASU, GLU, and CS modulates the pro-inflammatory response in equine
chondrocytes suggests the potential utility of this agent for down regulating the adverse
effects of antibiotics. The combination of ASU, GLU, and CS may alleviate
inflammation in equine joints following the use of enrofloxacin and amikacin.
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